EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases

Xinxuan Li iD, Jing Sun, Jianhui Zhao, Fangyuan Jiang, Meng Zhang, Hao Wu, Shuai Yuan, Xue Li, Juan Lu, Christos S Mantzoros iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Xinxuan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Inn…. Hauptthemen laut MEDLINE: Proteomics, Liver Diseases, Blood Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Fund for Distinguished Young Scholars of Zhejiang Province, National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The burden of chronic liver disease (CLD) is increasing. This study aims to identify protein markers for CLD and its progression, and develop a protein‐based risk prediction model. Materials and Methods We used proteome‐wide Mendelian randomization (MR), Bayesian colocalization and summary‐data‐based MR with proteomic data from deCODE Genetics to identify CLD‐related proteins. Multivariable MR was used to assess independent protein effects. Protein–protein interaction, druggability and mediation analyses were conducted to prioritise therapeutic targets. We further constructed a protein risk score to predict CLD and composite hepatic event outcomes, comparing its performance with existing clinical predictors.

Results

Genetically predicted levels of 16, 5 and 4 plasma proteins were associated with metabolic dysfunction‐associated steatotic liver disease (MASLD), alcoholic liver disease (ALD) and cirrhosis, respectively. IGSF3, FTCD, DCXR, ADH1B and ACY1 were associated with CLD progression. Genetically predicted five modifiable factors (body mass index, waist‐hip ratio, glycated haemoglobin, type 2 diabetes, leisure television watching) were associated with CLD‐related proteins. Proteomic‐based models showed high predictive performance for ALD (C‐index = 0.89), liver cancer (C‐index = 0.84) and liver failure (C‐index = 0.84) in a healthy population without liver diseases at baseline.

Conclusions

This study identified key circulating protein markers for CLD. Protein‐based profiling demonstrated strong predictive potential for CLD and related outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsLiver DiseasesBlood ProteinsHumansBiomarkersPrognosisLiver Diseases, AlcoholicMendelian Randomization AnalysisChronic DiseaseDisease ProgressionFemaleAlcohol DehydrogenaseMaleMembrane ProteinsLiver CirrhosisBayes TheoremFatty Liver

Stichwörter der Autor:innen

drug targetliver diseaseprediction modelproteome‐wide Mendelian randomization

Substanzen

BiomarkersADH1B protein, humanAlcohol DehydrogenaseMembrane ProteinsBlood Proteins

Autor:innen und Institutionen

  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the…
  • Center of Clinical Big Data and Analytics of the Second Affiliated Hospital, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, Changhai Hospital; National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China.
  • Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Xinxuan Li, Christos S Mantzoros

Förderung

  • Natural Science Fund for Distinguished Young Scholars of Zhejiang Province
  • National Natural Science Foundation of China
  • Science Fund for Distinguished Young Scholars of Zhejiang Province

Zitieren

APA

Li, X., Sun, J., Zhao, J., Jiang, F., Zhang, M., Wu, H., Yuan, S., Li, X., Lu, J., & Mantzoros, C. S. (2026). Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70696

Vancouver

Li X, Sun J, Zhao J, Jiang F, Zhang M, Wu H, et al. Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70696

BibTeX
@article{Li2026,
  author = {Li, Xinxuan and Sun, Jing and Zhao, Jianhui and Jiang, Fangyuan and Zhang, Meng and Wu, Hao and Yuan, Shuai and Li, Xue and Lu, Juan and Mantzoros, Christos S},
  title = {Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70696}
}
Kostenlos starten →